Effect of Repaglinide and Metformin Combination Therapy Compare With Repaglinide Monotherapy in Type 2 Diabetes Mellitus Treatment

• Main Authors: Yi-Chiao Su, 蘇鉯喬
• Other Authors: 陳宏一
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/pq5j3v

碩士 === 長榮大學 === 醫學研究所 === 106 === Purpose: According to the demographics from Taiwan National Health Insurance Administration, Ministry of Health and Welfare, there are approximately 138 million diagnosed diabetes people in Taiwan. To control hyperglycemia well can decrease renal, ocular, and neural complications. Combination therapy possibly provide more efficiency and cost-effectiveness. Methods: This is a randomized controlled study. The study group received Repaglinide 1mg/ Metformin 500 mg. The control group received Repaglinide 1mg.The efficacy was evaluated after 12 weeks of treatment, including HbA1C, FPG, and PPG. Results: There were 36 subjects completed the study. The HbA1c levels decreased 0.7 % in Repaglinide/Metformin group in 3 months and was comparable with Repaglinide monotherapy group (0.3%). The FPG and PPG decreased 18.2 mg/dL and 8.6 mg/ml, respectively, which were significantly improved after Repaglinide/Metformin treatment. Conclusions: Repaglinide/Metformin combination therapy provided adequate glycemic control when compared with Repaglinide monotherapy, and without further increase in hypoglycaemia complication.